Reevaluation of the cancer potency factor of toxaphene: Recommendations from a peer review panel

Toxicological Sciences

Volumn 55, Issue 1, 2000, Pages 3-16

  Goodman, Jay I ^a   Brusick, David J ^b   Busey, William M ^c   Cohen, Samuel M ^d   Lamb, James C ^e,g   Starr, Thomas B ^f  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Department of Environmental Air Quality   (United States)

^c EXPERIMENTAL PATHOLOGY LABORATORIES INC   (United States)

^d UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^e Jellinek Schwartz and Connolly Inc   (United States)

^f Environ   (United States)

^g Bouck and Lee Inc   (United States)

Author keywords

Cancer potency factor; Margin of exposure; Pathology working group (PWG); Toxaphene

Indexed keywords

CAMPHECLOR; ORGANOCHLORINE PESTICIDE;

ANIMAL MODEL; CANCER RISK; CHEMICAL CARCINOGENESIS; DOSE RESPONSE; ENVIRONMENTAL EXPOSURE; FEMALE; GENOTOXICITY; LIVER ADENOMA; LIVER TUMOR; MALE; NONHUMAN; PEST CONTROL; RAT; REVIEW;

EID: 0034104621     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/55.1.3     Document Type: Review

References (42)

1. Becker, F. F. (1982). Morphological classification of mouse liver tumors based on biological characteristics. Cancer Res. 42, 3918-3923.
2. Buchmann, A., Bauer-Hofmann, R., Mahr, J., Drinkwater, N. R., Luz, A., and Schwarz, M. (1991). Mutational activation of the c-Ha-ras gene in liver tumors of different rodent strains: correlation with susceptibility to hepatocarcinogenesis. Proc. Natl. Acad Sci. U S A 88, 911-915.
3. Clemmesen, J., and Hjalgrim-Jensen, S. (1978). Is phenobarbital carcinogenic? A follow-up of 8076 epileptics. Ecotoxicol. Environ. Saf. 1, 457-470.
4. Clemmesen, J., and Hjalgrim-Jensen, S. (1980). Epidemiological studies of medically used drugs. Arch. Toxicol. Suppl. 3, 19-25.
5. Cohen, S. M., and Ellwein, L. B. (1990). Cell proliferation in carcinogenesis. Science 249, 1007-1011.
6. Counts, J. L., and Goodman, J. L. (1995). Hypomethylation of DNA: A possible epigenetic mechanism involved in tumor promotion." In Growth Factors and Tumor Promotion: Implications fur Risk Assessment (R. M. McClain, T. J. Slaga, R. LeBoeuf, and H. Pitot, Eds.), pp. 81-101. Wiley-Liss, Inc., New York.
7. Counts, J. L., Sarmiento, J. I., Harbison, M. L., Downing, J. C., McClain, R. M., and Goodman, J. L. (1996). Cell proliferation and global methylation status changes in mouse liver after phenobarbital and/or choline-devoid, methionine-deficient diet administration. Carcinogenesis 17, 1251-1257.
8. de Geus, H. J., Besselink, H., Brouwer, A., Klungsoyr, J., McHugh, B., Nixon, E., Rimkus, G. G., Wester, P. G., and de Boer, J. (1999). Environmental occurrence, analysis, and toxicology of toxaphene compounds. Environ. Health Perspect. 107(Suppl 1), 115-144.
9. Doull, J., Bridges, B. A., Kroes, R., Golberg, L., Munro, I. C., Paynter, O. E., Pitot, H. C., Squire, R., Williams, G. M., and Darby, W. J. (1983). The relevance of mouse liver hepatoma to human risk: A report of the International Expert Advisory Committee to the Nutrition Foundation. The Nutrition Foundation, Inc., Washington. DC.
10. Epstein, S. S., Arnold, E., Andrea, J., Bass, W., and Bishop, Y. (1972). Detection of chemical mutagens by the dominant lethal assay in the mouse. Toxicol. Appl. Pharmacol. 23, 288-325.
11. Frith, C. H., and Ward, J. M. (1979). A morphologic classification of proliferative and neoplastic hepatic lesions in mice. J. Environ. Pathol. Toxicol. 3, 329-351.
12. Goldsworthy, T., Campbell, H. A., and Pitot, H. C. (1984). The natural history and dose-response characteristics of enzyme-altered foci in rat liver following phenobarbital and diethylnitrosamine administration. Carcinogenesis 5, 67-71.
13. Griffin, D. E. III, and Hill, W. E. (1978). In vitro breakage of plasmid DNA by mutagens and pesticides. Mutat. Res. 52, 161-169.
14. Griffin, R. J., Dudley, C. N., and Cunningham, M. L. (1995). Biochemical effects of the mouse hepatocarcinogen oxazepam: similarities to phenobarbital. Fundam. Appl. Toxicol. 29, 147-154.
15. Haseman, J. K., Winbush, J. S., and O'Donnell, M. W., Jr. (1986). Use of dual control groups to estimate false positive rates in laboratory animal carcinogenicity studies. Fundam. Appl. Toxicol. 7, 573-584.
16. Hedli, C. C, Snyder, R., Kinoshita, F. K., and Steinberg, M. (1998). Investigation of hepatic cytochrome P450 enzyme induction and DNA adduct formation in male CD/1 mice following oral administration of toxaphene. J. Appl. Toxicol. 18, 173-178.
17. Hooper, N. K., Ames, B. N., Saleh, M. A., and Casida, J. E. (1979). Toxaphene, a complex mixture of polychloroterpenes and a major insecticide, is mutagenic. Science 205, 591-593.
18. Houk, V. S., and DeMarini, D. M. (1987). Induction of prophage lambda by chlorinated pesticides. Mutat. Res. 182, 193-201.
19. Maekawa, A., Onodera, H., Ogasawara, H., Matsushima, Y., Mitsumori, K., and Hayashi, Y. (1992). Threshold dose dependence in phenobarbital promotion of rat hepatocarcinogenesis initiated by diethylnitrosamine. Carcinogenesis 13, 501-503.
20. Maronpot, R. R., Montgomery, C. A., Jr., Boorman, G. A., and McConnell, E. E. (1986). National Toxicology Program nomenclature for hepatoproliferative lesions of rats. Toxicol. Pathol. 14, 263-73.
21. McClain, R. M. (1990). Mouse liver tumors and microsomal enzyme-inducing drugs: experimental and clinical perspective with phenobarbital. Prog. Clin. Biol. Res. 331, 345-365.
22. McClain, R. M. (1994). Mechanistic considerations in the regulation and classification of chemical carcinogens. In Nutritional Toxicology (F. N. Kotsonis, M. Mackey and J. Hjelle, Eds.), pp. 273-304. New York, Raven Press,
23. Mortelmans, K., Haworth, S., Lawlor, T., Speck, W., Tainer, B., and Zeiger, E. (1986). Salmonella mutagenicity tests: II. Results from the testing of 270 chemicals. Environ. Mutagen. 8(Suppl. 7), 1-119.
24. National Cancer Institute (1979). Bioassay of Toxaphene of Possible Carcinogenicity. Technical Report Series No. 37.
25. Olsen, J. H., Schulgen, G., Boice, J. D., Jr., Whysner, J., Travis, L. B., Williams, G. M., Johnson, F. B., and McGee, J. O. (1995). Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma. Cancer Res. 55, 294-297.
26. Olsen, J. H., Wallin, H., Boice, J. D., Jr., Rask, K., Schulgen, G., and Fraumeni, J. F., Jr. (1993). Phenobarbital, drug metabolism, and human cancer. Cancer Epidemiol. Biomarkers. Prev. 2, 449-452.
27. Reddy, M. V., and Randerath, K. (1986). Nuclease P1-mediated enhancement of sensitivity of 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis 7, 1543-1551.
28. Samosh, L. V. (1974). Chromosome aberration and the character of satellite associations following accidental exposure of the human body to polychlorocamphene. Tsitol. Genet. 8, 24-27.
29. Sobti, R. C., Krishan, A., and Davies, J. (1983). Cytokinetic and cytogenetic effect of agricultural chemicals on human lymphoid cells in vitra: II. Organochlorine pesticides. Arch. Toxicol. 52, 221-231.
30. Steinel, H. H., Arlauskas, A., and Baker, R. S. (1990). SCE induction and cell-cycle delay by toxaphene. Mutat. Res. 230, 29-33.
31. 1 (B6C3F1) mice. J. Natl. Cancer Inst. 66, 1175-1181.
32. Trosko, J. E., Jone, C., and Chang, C. C. (1987). Inhibition of gap junctional-mediated intercellular communication in vitro by aldrin, dieldrin and toxaphene: a possible cellular mechanism for their tumor-promoting and neurotoxic effects. Mol. Toxicol. 1, 83-93.
33. U.S. Environmental Protection Agency (1978). Occupational exposure to toxaphene. A Final Report by the Epidemiologic Studies Program. Human Health Effects Monitoring Branch, Benefits and Field Studies Division, OPP, OTS, EPA.
34. U.S. Environmental Protection Agency (1996a). Proposed Guidelines for Carcinogen Risk Assessment. Fed. Register 61, 17960-18011.
35. U.S. Environmental Protection Agency (1996b). Assessment of thyroid follicular cell tumors. A draft report prepared by the Risk Assessment Forum.
36. Vesselinovitch, S. D., and Mihailovitch, N. (1983). Kinetics of diethylnitrosamine hepatocarcinogenesis in the infant mouse. Cancer Res. 43, 4253-4259.
37. Ward, J. M. (1996). Can so-called nongenotoxic hepatocarcinogens induce mouse liver neoplasms? Toxicol. Pathol. 24, 505.
38. 1 (B6C3F1) mice. J. Natl. Cancer Inst., 63, 849-854.
39. Ward, J. M., Shibata, M. A., and Devor, D. E. (1996). Emerging issues in mouse liver carcinogenesis. Toxicol. Pathol. 24, 129-137.
40. Waritz, R. S., Steinberg, M., Kinoshita, F. K., Kelly, C. M., and Richter, W. R. (1996). Thyroid function and thyroid tumors in toxaphene-treated rats. Regul. Toxicol. Pharmacol. 24, 184-192.
41. 32P-postlabeling assay. Toxicol. Appl. Pharmacol. 148, 14-23.
42. Whysner, J., Ross, P. M., and Williams, G. M. (1996). Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther. 71, 153-191.